Sponsor or institution
Clinical trials and research at ETOP IBCSG Partners Foundation
As of November 12, 2026, Find a Trial lists 5 clinical trials run by ETOP IBCSG Partners Foundation that are recruiting, at sites in 14 countries (most in Italy (5), Switzerland (5), France (4)). By phase: Phase 3 (3), Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 14Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Tarlatamab for previously treated extensive-stage small cell lung cancer with ECOG performance status 2 | Phase 2 | Angers and 18 other locations | Recruiting | Oct 2, 2025 |
| Adjuvant cemiplimab after complete surgery for stage II–IIIA non-small cell lung cancer in patients who have not had chemotherapy | Phase 3 | Vienna and 34 other locations | Recruiting | Apr 17, 2025 |
| Evaluating Durvalumab After Chemotherapy and Surgery for Early-stage Lung Cancer | Phase 3 | Camperdown, New South Wales and 43 other locations | Recruiting | Feb 28, 2024 |
| Niraparib with Anti-PD-L1 for SLFN11-positive Extensive-stage SCLC | Phase 2 | Angers and 17 other locations | Recruiting | Feb 8, 2023 |
| Combining immunotherapy or targeted therapy with stereotactic radiosurgery for brain metastases from melanoma or lung cancer | Phase 3 | Naples and 14 other locations | Recruiting | Aug 31, 2022 |
All recruiting trials (5)
-
Tarlatamab for previously treated extensive-stage small cell lung cancer with ECOG performance status 2
This trial tests whether tarlatamab can help people with extensive-stage small cell lung cancer who progressed after one platinum‑etoposide plus immune checkpoint inhibitor regimen and have an ECOG performance status of 2.
-
Adjuvant cemiplimab after complete surgery for stage II–IIIA non-small cell lung cancer in patients who have not had chemotherapy
This trial tests whether giving cemiplimab after complete surgery can help prevent cancer from coming back in people with stage II–IIIA non-small cell lung cancer who did not receive chemotherapy.
-
Evaluating Durvalumab After Chemotherapy and Surgery for Early-stage Lung Cancer
This study is testing if adding an immunotherapy drug called durvalumab after chemotherapy and surgery can help people with early-stage lung cancer live longer without the disease coming back.
-
Niraparib with Anti-PD-L1 for SLFN11-positive Extensive-stage SCLC
This study is testing if adding a pill called niraparib to an existing treatment can help people with a specific type of advanced small cell lung cancer feel better after their initial therapy.
-
Combining immunotherapy or targeted therapy with stereotactic radiosurgery for brain metastases from melanoma or lung cancer
This study is testing if combining a type of brain surgery with standard cancer treatments can help people with brain metastases from melanoma or lung cancer live longer and feel better.
Quick answers
How many clinical trials run by ETOP IBCSG Partners Foundation are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 14 countries. The most sites are in Italy (5 trials), Switzerland (5 trials), France (4 trials), Spain (4 trials), Austria (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 3, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.